Manipulated drugs for newborns
Main Article Content
Abstract
Introduction: Newborn patients admitted to Neonatal Intensive Care
Units are very vulnerable to pharmaceutical forms since there are few drugs with adequate pharmaceutical forms for this population. Objective: To describe the prescriptions of pharmaceutical compounding for newborn patients and to verify their pharmaco technical preparation. Method: Retrospective descriptive study. Data
were obtained from prescriptions of patients from six hospitals in Rio de Janeiro, attended at a pharmacy with handling between June and November 2017. Results: The study included 51 prescriptions, comprising 57 formulations of 17 different drugs. All formulations were prepared in pharmaceutical forms for oral administration. Of
these, 65% in the form of aqueous solution, 24.5% of suspension and 10.5% of syrup. The drugs caffeine 36.85%, captopril 7.1%, and pyridoxine 5.3% were the most frequent as solution. As suspension, coenzyme Q10 with 7.1% was the most frequent, and among vehicles with sucrose, propranolol with 7.1%. Among the excipients, glycerin
with 58,0% was the most used. Excipient minimums were used to stabilize the formulations, given the little evidence of the use of drugs and excipients for use in this age group. Conclusions: All drugs described in the formulations were intended for liquid dosage forms. The development of these formulations allowed to meet the specific needs of each patient, requiring, however, the use of excipients as
harmless as possible.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
1. Balan S, Hassali MA, Mak VSL. Challenges in pediatric drug use: a pharmacist point of view. Res Social Adm Pharm. 2017; 13(3):653-655.
2. Souza Pereira A.C. et al. Medicamentos magistrais em recém-nascidos e crianças hospitalizados. Rev Paul Pediatr. 2016; 34(4):403-407.
3. Carvalho CG, Ribeiro MR, Bonilha MM, Fernandes Jr M, Procianoy RS, Silveira RC. Use of off-label and unlicensed drugs in the neonatal intensive care unit and its association with severity scores. J Pediatr. 2012; 88(6):465-70.
4. Magalhães J, Rodrigues AT, Roque F, Figueiras A, Falcão A, Herdeiro MT. Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review. Eur J Clin Pharmacol. 2015; 71:1-13.
5. Costa PQ, Lima JES, Coelho HLL. Prescrição e preparo de medicamentos sem formulação adequada para crianças: um estudo de base hospitalar. Brazilian Journal of Pharmaceutical Sciences. 2009; 45(1):57-66.
6. Nahata MC, Allen Jr LV. Extemporaneous drug formulations. Clinical Therapeutics. 2008; 30(11):2112-2119.
7. Pinto S, Barbosa CM. Medicamentos manipulados em pediatria, estado actual e perspectivas futuras. Arquivos de Medicina. 2008; 22(33):75-84.
8. BRASIL. Agência Nacional de Vigilância Sanitária. Resolução - RDC nº 67, de 8 de outubro de 2007. Regulamento Técnico sobre Boas Práticas de Manipulação de Preparações Magistrais e Oficinais para uso Humano em Farmácia e seus Anexos. Diário Oficial da União, Brasília, n. 195, p.2 9-58, 9 out 2007. Disponível em: <http://portal.anvisa.gov.br>. Acesso em: 28 fev. 2015.
9. Blanco-Reina E, Medina-Claros AF, Veja-Jiménez MA, Ocana-Riola R, Márquez-Romero EI, Ruiz Extremara A. Utilización de fármacos en niños en cuidados intensivos: estudio de las prescripciones off-label. Med Intensiva. 2016; 40(1):1-8.
10. Britto JF et al. Utilização de preparações magistrais extemporâneas em pacientes pediátricos de um hospital público. Rev. Saúde.Com. 2017; 13(1):797-805.
11. Nahata MC. Safety of ''inert'' additives or excipients in paediatric medicines. Arch Dis Child Fetal Neonatal. 2009; 94(6):392-3.
12. Cuzzolin L, Agostino R. Off-label and unlicensed drug treatments in Neonatal Intensive Care Units: an Italian multicentre study. Eur J Clin Pharmacol. 2016; 72:117-123. DOI 10.1007/s00228-015-1962-4
13. Schweigertova J, Durisova A, Dolnikova D, Ondriasova E, Balazova M. Off-label and unlicensed use of medicinal products in the neonatal setting in the Slovak Republic. Pediatrics International. 2016; 58: 126-13.
14. Costa PQ, Rey LC, Coelho HL. Lack of drug preparations for use in children in Brazil. Jornal de Pediatria, Rio de Janeiro. 2009; 85(3):229-235.
15. Sathapanapitagkit N, Prokati M, Leanpolchareanchai J, Chantasart D, Laohajeeraphan M, Suksiriworapong J. Chemical and physical stability investigations of captopril extemporaneous suspension for oral administration. Mahidol Univ J Pharm Sci. 2015; 42(3):126-134.
16. Ji Y, Chen S, Xiang B, Yang Y, Qiu L. Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study. Scientific Reports. 2017; 7(1503):1-8.
17. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 6. ed. Pharmaceutical Press. 2009.
18. Nellis G, Metsvaht T, Varendi H, Toompere K, Lass J, Mesek I, NunnAJ, Turner MA, Lutsar. Potentially harmful excipients in neonatal medicines: a pan-European observational study. Arch Dis Child. 2015; 100(7):694-699.
19. Souza Jr, A, Santos D, Fonseca S, Medeiro s M, Batista L, Turner M, Coelho H. Toxic excipients in medications for neonates in Brazil. Eur J Pediatr. 2014; 173(7):935-945.
20. Sherab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009; 10(2):256-259.
21. Garcia-Palop B, Polanco EM, Ramirez CC, Poy MJC. Harmful excipients in medicines for neonates in Spain. Int. J Clin Pharm. 2016; 38(2):238-242.
22. Carvalho CG, Ribeiro MR, Bonilha MM, Fernandes Jr M, Procianoy RS, Silveira RC. Use of off-label and unlicensed drugs in the neonatal intensive care unit and its association with severity scores. Jornal de Pediatria, Rio de Janeiro. 2012; 88(6):465-70